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ABSTRACT
Many antibiotics inhibit bacterial growth by binding to the ribosome and interfering with protein
biosynthesis. Macrolides represent one of the most successful classes of ribosome-targeting
antibiotics. The main clinically-relevant mechanism of resistance to macrolides widely employed
by pathogens is dimethylation of the 23S rRNA nucleotide A2058 located in the drug binding site,
a reaction catalyzed by the Erm-type rRNA methyltransferases. Here, we present the first crystal
structure of the Erm-dimethylated 70S ribosome at 2.4Å resolution together with the structures of
unmethylated 70S ribosome functional complexes alone and in combination with several
macrolides. Altogether, our structural data do not support the previous models proposed to explain
Erm-mediated mechanism of macrolide resistance. Instead, we present a principally new
explanation of how A2058-dimethylation confers resistance to macrolides. Moreover, our highresolution structures of two macrolide antibiotics bound to the unmodified ribosome revealed a
previously unknown role of the universal desosamine moiety in drug binding. The newly
understood mode of interaction of macrolide’s desosamine with the ribosome lays a foundation
for the rational knowledge-based design of macrolides that can overcome Erm-mediated resistance.

KEYWORDS
Macrolide; antibiotic; resistance; methylation; A2058; 23S rRNA; 70S ribosome; X-ray structure;
inhibition of translation; peptidyl transferase center; nascent peptide exit tunnel.
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INTRODUCTION
Antibiotics prevent bacterial growth by inhibition of vital cellular processes. Many of them target
functionally important sites on the bacterial 70S ribosome and block protein synthesis1. Prominent
among these inhibitors are macrolide antibiotics, a large family of natural and semi-synthetic
compounds that consist of 12- to 16-membered macrolactone rings decorated with various side
chains. Macrolides are widely used for the treatment of human community-acquired bacterial
respiratory tract infections, including those that arise as complications of viral diseases2,3. These
antibacterials achieve their inhibitory action by binding in the nascent peptide exit tunnel (NPET)
of the bacterial ribosome and interfering with the progression of some growing polypeptides
through this tunnel4. Several mechanisms of resistance to macrolides have been described,
including efflux5,6, enzymatic degradation of the drugs7,8, or alteration of the drug-binding pocket
through mutations6,9. However, the most abundant among bacterial pathogens and clinically most
relevant mechanism of resistance against macrolides is based on mono- or dimethylation of the N6
position of a specific adenine residue (A2058) of the 23S rRNA (E. coli numbering of the
nucleotides is used throughout) (Fig. 1a)10-12. The modification of this nucleotide located in the
macrolide binding pocket in the NPET is catalyzed by the Erm-type rRNA methyltransferases13,14.
Dimethylation, in particular, dramatically reduces the binding of the macrolides to the ribosome,
rendering cells highly resistant to these drugs15,16. In addition to macrolides, the same modification
confers resistance to two other structurally-unrelated classes of ribosome-targeting antibiotics,
which also bind in the NPET, specifically lincosamides and streptogramins B (hence this type of
resistance is known as MLSB)17.
Significant efforts have been invested in developing newer generations of semi-synthetic
macrolide antibiotics with improved binding properties, e.g. ketolides2. These drugs show
improved activity against a variety of Gram-positive and Gram-negative pathogens, including
those carrying inducible erm genes3,18. Nevertheless, bacteria that constitutively express Ermmethyltransferase enzymes that dimethylate A2058 still demonstrate high levels of resistance to
all the known macrolide antibiotics19,20. Therefore, there is a pressing demand for the development
of new macrolides active against Erm-modified ribosomes of resistant pathogens. Understanding
at a structural level the detailed molecular mechanism of Erm-mediated resistance to macrolides
would provide key insights that are essential for the development of such compounds.
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Previous attempts to explain the effect of A2058-methylation on drug binding were based on the
structures of unmodified bacterial ribosomes complexed with various macrolides21-26. According
to the prevailing steric clash model, the positions of the methyl group(s) added to the exocyclic
N6 amino group of A2058 would overlap either with the 2´-hydroxyl group or the dimethyl-amino
group of the desosamine sugar of a macrolide21. Due to this collision, the drug molecule should be
unable to fully accommodate into its binding pocket and form hydrogen (H-) bond(s) with the
A2058 and, therefore, cannot stably bind to the Erm-modified ribosome. However, the simplistic
steric clash model is hard to be reconciled with the available experimental data. For instance,
macrolide derivatives with 2´-deoxy or 3´-desmethyl desosamine, which were designed to reduce
the steric clash with dimethylated A2058, were inactive against Staphylococcus aureus strains
constitutively expressing Erm methyltransferase27. An alternative model is based on molecular
dynamics simulation studies that suggest methylation of A2058 would result in complex structural
rearrangements of the entire macrolide binding pocket, making drug binding impossible28. This
model could rationalize the observed Erm-mediated resistance to all antibiotics of the MLSB group,
macrolides, lincosamides, and streptogramins B, which bind at the overlapping sites within the
NPET of the bacterial ribosome. Although an attractive hypothesis, such structural rearrangements
have never been experimentally verified or observed structurally.
By finding the conditions for expressing functionally-active Erm-methyltransferase in
thermophilic bacterium Thermus thermophilus, and solving the structures of the Erm-modified
(A2058-dimethylated) and unmethylated 70S ribosome in complex with mRNA and
aminoacylated tRNAs alone and in combination with macrolides, we demonstrate that neither of
these models is likely to be correct. Instead, we present a principally new explanation of how
A2058-dimethylation confers resistance to macrolide antibiotics. Not only we uncovered the
mechanism of Erm-mediated macrolide resistance, but also our high-resolution structures of two
macrolide antibiotics bound to the unmodified ribosome revealed a previously unknown role of
the universal desosamine side chain in drug binding. The newly understood mode of interaction of
this macrolide’s moiety with the ribosome provides pivotal information for the design of
macrolides that can overcome Erm-mediated resistance.
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RESULTS AND DISCUSSION
Engineering of the T. thermophilus strain expressing active Erm rRNA methyltrasnferase.
Erm enzymes are expressed in a broad spectrum of pathogenic bacterial clinical isolates as well as
in non-pathogenic native bacterial species where they produce strong resistance to macrolides29.
The Erm methyltransferase operates during ribosome assembly because in the mature ribosome
the target of Erm action, A2058 of the 23S rRNA, is inaccessible to the enzyme30. To obtain a
structure of the Erm-modified ribosome, we have chosen the Gram-negative thermophilic
bacterium T. thermophilus (Tth) as our experimental model because Tth ribosomes have been
successfully used in the past for structure determination and produce the highest-resolution
data31,32. However, our attempts to express a functionally active Erm enzyme PikR2 from the
mesophilic bacterium Streptomyces venezuelae33 in this thermophilic host have failed, presumably
due to protein instability at high growth temperature (Supplementary Table 1). To overcome this
problem, we selected four erm-like genes from genomes of bacteria adapted for growth at elevated
temperatures (Fig. 1b; Supplementary Figs. 1, 2; Supplementary Table 1). The genes were
synthesized, cloned into the pBGAA1 vector34 and expressed in T. thermophilus (Fig. 1c).
Macrolide susceptibility testing of the plasmid-transformed Tth cells showed that the expression
of an erm-like gene from Bifidobacterium thermophilum (referred hereafter as ErmBth) resulted
in a strong resistance to the macrolide antibiotic erythromycin (ERY) increasing the minimal
inhibitory concentration (MICERY) for the ErmBth-expressing cells 1000-fold compared with the
control cells carrying the empty vector (Supplementary Table 2).
To verify that the observed macrolide resistance results from the specific methyltransferase
activity of ErmBth, we used a primer extension analysis to biochemically assess A2058
modification35. This method is based on the arrest of reverse transcriptase (RT) progression on the
rRNA template due to its inability to incorporate a complementary nucleotide into the synthesized
cDNA at the N6-dimetylated adenine. The expected cDNA arrest product of the RT reaction
corresponding to the A2058 position was observed only on the 23S rRNA isolated from the Tth
cells expressing ErmBth (Fig. 1d, lanes 2 and 3), confirming that ErmBth has the desired A2058targeting methylation activity. Moreover, we found that the level of A2058-dimethylation can be
significantly increased by growing the ErmBth-expressing cells in the presence of sub-inhibitory
concentrations of ERY (Fig. 1d, e). By optimizing ERY concentration and growth temperature of
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the ErmBth-expressing T. thermophilus strain, we managed to reach the level of A2058
dimethylation as high as ~60% (Fig. 1e). Since X-ray crystallography is essentially an averaging
technique, structural data could be confidently interpreted even if only half of the ribosomes are
N6-dimethylated at A2058.

Structure of the m62A2058 70S ribosome.
We used our T. thermophilus strain expressing ErmBth-methyltransferase to purify 70S ribosomes
for structural analysis. These were crystallized using previously published conditions31,36 in a
functional state that corresponds to a pre-peptide bond formation state of the ribosome, in which
unreacted fMet-tRNAiMet (in the form of its non-hydrolyzable analog fMet-NH-tRNAiMet) occupies
the P-site, while non-hydrolyzable Phe-NH-tRNAPhe is bound to the A-site. By applying our recent
improvements in complex preparation (see Materials and Methods), we were able to obtain crystal
structures of the A2058-dimethylated and unmethylated Tth 70S ribosome in complex with mRNA
and aminoacylated tRNAs determined at 2.4Å and 2.5Å resolution, respectively (Supplementary
Table 3). For a more accurate understanding of drug-ribosome interactions, we determined
structures of the unmethylated ribosomal functional complexes bound with two macrolide
antibiotics, telithromycin (TEL) or erythromycin (ERY). These structures have been solved at
2.6Å and 2.55Å resolution, respectively, and represent the highest resolution 70S ribosomemacrolide structures available to date (Supplementary Table 3).
At this resolution, methylation of nucleotide bases can be directly visualized in the unbiased
electron density maps (Fig. 2a, green mesh), and the N6-dimethylated A2058 (m62A2058) can be
confidently modeled in our structure (Fig. 2a, b; Supplementary Fig. 3a). Due to the presence of
aminoacylated tRNAs (Supplementary Fig. 4), our structure of the WT ribosome with the
unmodified A2058 reached a higher resolution than the previously reported structure36, and clearly
shows the position and orientation of the unmethylated A2058 residue which, therefore, serves as
our reference point (Fig. 2c, d). Additional evidence for the presence of the methyl groups on
m62A2058 comes from the comparison of electron densities for the methylated m62A2058 and the
unmethylated A2057 in the 23S rRNA (negative control, Supplementary Fig. 3b) or the N6dimethylated A1519 in the 16S rRNA (positive control, Supplementary Fig. 3c) of the same
structure. In contrast to the predictions of MD simulations that A2058 modification would lead to
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a dramatic rearrangement of the macrolide binding site28, no significant changes were observed in
the orientations of the 23S rRNA nucleotides or the amino acid residues of the ribosomal proteins
L4 and L22 neighboring A2058 in the ErmBth-modified ribosome (Fig. 3a, b). Most importantly,
m62A2058 appears in the same orientation relative to its neighbors as compared to the reference
(unmodified) structure (Fig. 3c, d). Because A2058 methylation has been proposed to cause longrange structural rearrangements and affect the functionality of the ribosome28, we also examined
the ErmBth-modified ribosome for shifts in any of the key functional nucleotides around the PTC
but failed to find any changes. Altogether our high-resolution structure of the A2058-dimethylated
ribosome shows that the Erm-catalyzed rRNA modification does not cause any significant
structural rearrangements in the macrolide binding site in the NPET.
Despite the fact that macrolide antibiotics have many H-bond donors and acceptors (Fig. 4a), there
is only a single H-bond (between the 2´- OH of the desosamine sugar of a macrolide and the N1
atom of the A2058) that has been consistently observed in all structures of ribosome-bound
macrolides (Fig. 4b)21-25,32. It has been suggested previously that the methyl groups of the N6dimethylated A2058 residue can sterically clash with either the 2´-OH or the 3´-dimethyl-amino
group of desosamine, leading to disruption of this critical H-bond and disturbing macrolide
binding21,22. However, superposition of our structure of A2058-dimethylated Tth ribosome with
that of the unmethylated Tth ribosome bound to ERY (or TEL) shows no overlap between the
m62A2058 methyl groups and the desosamine 2´-OH (Fig. 4b, c) or the desosamine dimethylamino groups (Fig. 4b, d). It is important to point out that, because the N6-nitrogen of the N6dimethylated (and also N6-monomethylated) adenine residue has sp2 geometry37,38, the two methyl
groups attached to the exocyclic amine of m62A2058 are planar with the adenine heterocycle ring.
Furthermore, the sp2 geometry of the N6-atom does not allow free rotation around the C6-N6 bond
in m62A2058, excluding any alternative orientations of the methyl groups that could potentially
result in a sterical clash with a macrolide. Thus, the analysis of the high-resolution structures of
the ribosome-bound macrolides in complex with the unmodified ribosome and antibiotic-free
A2058-dimethylated ribosome brings us to the conclusion that dimethylation of the exocyclic
amine of A2058 by Erm methyltransferase does not result in a steric clash with desosamine sugar
of the macrolide antibiotic or the loss of the H-bond between the desosamine 2´-OH and the A2058
residue proposed previously to explain Erm-mediated resistance to macrolides.
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Deciphering the role of the desosamine dimethyl-amino group in macrolide binding.
The dimethyl-amino group of desosamine has been shown previously to be crucial for the
interaction of macrolides with the ribosome39. However, its exact role in drug binding has never
been revealed. It is evident from the previous structural studies that no ribosomal component is
directly involved in the interaction with this group. Moreover, by comparing all the available
structures of ribosome-macrolide complexes, we noticed a significant variability in the orientation
of this chemical group (Supplementary Figs. 5, 6), possibly due to varying interpretations of the
electron density maps rather than differential placement of this chemical moiety. Notably, in none
of the previous structures 3´-dimethyl-amino group of desosamine directly interacts with any of
the ribosome counterparts.
In our 2.55Å and 2.6Å resolution structures of ribosome-bound ERY or TEL, both drug molecules
are located in the canonical macrolide-binding pocket in the NPET near the PTC23-25. Interestingly,
the shape of the electron density around the desosamine dimethyl-amino group clearly shows that
the nitrogen lone pair of electrons (and this group as a whole) is pointed in the direction of A2058
(Fig. 5a, b, middle insets; Supplementary Fig. 7). This orientation is different from that in some
of the previous structures, in which this group is oriented towards the exocyclic N6-amino group
of the adjacent A2059 (Supplementary Fig. 6a, b)22-25,32,40. However, it resembles the orientation
of this moiety in the 2.4Å-resolution structure of azithromycin bound to Haloarcula marismortui
50S ribosomal subunit (Supplementary Fig. 6c)22 or the 3.0Å- resolution structure of this
macrolide bound to Tth 70S ribosome (Supplementary Fig. 6d)23.
Importantly, the high quality of the electron density maps of the new 70S-ERY and 70S-TEL
structures allowed us to detect a distinct peak of positive electron density in close proximity to the
dimethyl-amino moiety of desosamine in both complexes (Fig. 5a, b). We interpreted this electron
density as a tightly coordinated water molecule based on the following criteria: (i) it fits snuggly
between the two potential H-bond acceptors (nitrogen of the dimethyl-amino group of desosamine
and one of the non-bridging oxygens of the G2505 phosphate) and a strong H-bond donor
(exocyclic N6 amino group of the A2058); (ii) the distances between the aforementioned atoms
and a putative water molecule in this location are all within the ideal range for H-bonds (2.5-3.5Å);
(iii) the orientations of the proposed H-bonds correspond to the ideal tetrahedral geometry of the
sp3-hybridized oxygen atom of a water molecule (Fig. 5a, b); (iv) ideal planar geometry with the
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heterocycle ring for the H-bond from the A2058 N6 donor to the oxygen acceptor of the modeled
water (Fig. 5a, b, middle insets); (v) the observed electron density is too weak to be attributed to
more electron-dense ions, such as Mg2+ or K+. Thus, because of the high resolution of our new
70S-ERY and 70S-TEL structures, it becomes evident that the high affinity of desosaminecontaining macrolides to the ribosome is mediated by a strong H-bond mediated by the water
molecule, which in turn is tightly coordinated by the exocyclic N6-amino group of A2058 and the
phosphate of G2505 of 23S rRNA (Fig. 5c). This critical, water-mediated contact between a
macrolide molecule and the ribosome, which has never been reported before, illuminates the
previously obscure role of the dimethyl-amino moiety of desosamine in macrolide binding to the
ribosome. Consistent with our observations, re-evaluation of the electron density maps of
previously published ribosome-macrolide complex structures revealed the presence of this same
water molecule; a peak of positive electron density can be seen in the same location in all structures
with resolution ≤ 2.7Å22,32. However, it is the high quality of our structural data, which allows for
interpretation of this density peak as a water molecule and reveals the possibly critical role of this,
previously overlooked, player in macrolide binding.

Structural basis for Erm-mediated macrolide resistance.
The discovery of a key water molecule that mediates macrolide binding to the ribosome and the
solved structure of the A2058-dimethylated ribosome allows a conceptually new rationalization of
Erm-mediated macrolide resistance in molecular terms. In the unmethylated ribosome, the N6amino group of the A2058 residue serves as an H-bond donor that shares one proton with the H2O
oxygen atom (Fig. 5c, e). This water molecule, in turn, shares one of its protons with the G2505
phosphate and the other proton with the dimethyl-amino group of a macrolide. Dimethylation (but
not monomethylation) of the N6-amino group of the A2058 by Erm-methyltransferases makes
coordination of this water molecule impossible due to the inability of the A2058 dimethyl-amino
group to serve as a proton donor. Furthermore, one of the m62A2058 methyl groups would
physically displace the water molecule (Fig. 5d, e), leaving the dimethyl-amine of desosamine
without the mediator of its interaction with the G2505 phosphate. The lack of such interaction in
the A2058-dimethylated ribosome would have a strong negative effect on the free energy of the
drug-ribosome complex leading to macrolide resistance. The same water molecule could also be
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observed in the current structure of wild-type ribosome in the absence of a macrolide. Therefore,
it is conceivable that it could be important for normal ribosome functioning by stabilizing the local
structure of the 23S rRNA. Displacement of this water molecule by dimethylation of A2058 and
the resulting alteration in the local 23S rRNA structure and/or the chemical makeup of the NPET
could potentially account for reduced fitness of cells expressing Erm methyltransferase, linked to
aberrant translation of specific proteins41.
Besides the Erm-catalyzed dimethylation of A2058, mutations of this nucleotide to guanine,
cytosine, or uracyl also result in macrolide resistance42,43. The discovered water-mediated
interaction of macrolides with the ribosome allows re-evaluation of the mechanism of antibiotic
resistance caused by these mutations (Supplementary Fig. 8a). In silico modeling of the A2058
mutations reveals that pyrimidine bases at this position would be placed too far from the
desosamine moiety of a macrolide to establish any interactions with the drug (including watermediated contacts) (Supplementary Fig. 8c, d). Replacing A2058 with guanine was proposed to
lead to a steric clash with the C4 carbon of the macrolactone ring (Supplementary Fig. 8b)22. Our
structures show that in addition to this mechanism, G2058 would not be able to coordinate the
critical molecule of water the same way as adenine because the O6 atom of guanine cannot serve
as an H-bond donor (Supplementary Fig. 8b).
Erm-mediated dimethylation of A2058 residue is the major clinical mechanism of bacterial
resistance not only to macrolides but also to lincosamides and type B streptogramins. Comparison
of our structure of the A2058-dimethylated 70S ribosome with the previously reported structure
of the ribosome-bound lincosamide antibiotic clindamycin24 reveals a significant steric clash
between one of the methyl groups of m62A2058 and the 2´- and 3´-OH groups of the 7-chloro-1methylthio-lincosamine moiety of the drug (Supplementary Fig. 9a, b). In contrast to macrolides
and type B streptogramins, a similar high level of resistance to lincosamides could be achieved not
only by dimethylation but also by monomethylation of A205829,44. Due to the sp2 geometry of the
N6-atom, the single methyl group of the monomethylated A2058 residue can exist in two
alternative conformations: syn-methyl (with the methyl group oriented towards the Watson-Crick
edge of the nucleotide) and anti-methyl (with the methyl group rotated towards the N7-atom of
the adenine base )45. Importantly, it is only the syn-methyl conformation of the N6-methyl group
of monomethylated A2058 that would clash with the ribosome-bound lincosamide drug, whereas
the N6-methyl group in the anti-methyl conformation not only avoids the clash but could also
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retain all H-bonding capabilities potentially critical for the lincosamide drug binding
(Supplementary Fig. 9b). However, because of a steric hindrance from the N7-atom of adenine,
the syn-methyl conformation is energetically more favorable than the anti-methyl conformation45.
Unlike macrolides, lincosamides, whose binding to the ribosome is characterized by 3-order of
magnitude lower affinity46,47, apparently cannot overcome the energy needed to re-orient the
methyl group of N6-monomethylated A2058 into unfavorable anti-methyl conformation. Thus,
N6-monomethylation of the A2058 is likely to cause resistance to lincosamides via the same steric
hindrance mechanism as the dimethylation of the same adenine residue (Supplementary Fig. 9a,
b).
Interestingly, similar superpositioning of the structure of the A2058-dimethylated ribosome with
the published structure of type B streptogramin antibiotic quinupristin complexed to the
ribosome26 does not show any overlap between m62A2058 and the drug (Supplementary Fig. 9c,
d). Moreover, the N6-dimethyl is located on the opposite side of the A2058 nucleotide relative to
the closest dimethyl-amino-phenylalanine moiety of the ribosome-bound quinupristin
(Supplementary Fig. 9d). This moiety likely forms a Van-der-Waals contact with the N3 atom of
the A2058 residue. However, because the A2058 nucleotides in the two superimposed structures
have the same conformations, the N6-dimethylation of A2058 is unlikely to perturb this contact
(Supplementary Fig. 9d). Overall, structural analysis shown in Supplementary Fig. 9c does not
reveal disruptions of any critical contacts of the drug with the ribosome that could be caused by
Erm-catalyzed A2058 dimethylation and, thus, does not offer a straightforward explanation for the
molecular mechanism of the Erm-mediated streptogramin B resistance, which still remains
enigmatic. Although Erm-mediated dimethylation of A2058 renders bacterial ribosomes resistant
to macrolides, lincosamides, and streptogramins B, the actual mechanism of resistance at a
molecular level appears to be different for each class of NPET-targeting antibiotics.
Altogether, our structural study uncovering the molecular mechanism of Erm-mediated resistance
could be a starting point for the rational knowledge-based development of new MLSB antibiotics
active against challenging drug-resistant pathogens. This quest will be likely additionally
stimulated by the recently discovered new combinatorial approaches for the synthesis of novel
macrolides48, streptogramins49, and other drugs. Interestingly, all previous attempts to make
macrolides active against Erm-modified ribosomes relied on derivatization of the existing
macrolides to provide additional anchoring points that improved their overall affinity50. However,
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very few of the derivatizations affected the desosamine likely due to its importance in overall drug
binding. Unfortunately, the affinities of the resulting semi-synthetic macrolides of a newer
generation (such as telithromycin or solithromycin) to the modified ribosome are too low for
successful use of these drugs for the treatment of infections caused by pathogens that express Erm
methyltransferase19,51,52. Now, when the precise role of the desosamine sugar in macrolide binding
to the ribosome is uncovered, this information may become instrumental in the designing of
macrolides that can overcome Erm-mediated resistance.
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codes: 6XHV for the A2058-dimethylated T. thermophilus 70S ribosome in complex with mRNA,
aminoacylated A-site Phe-NH-tRNAPhe, aminoacylated P-site fMet-NH-tRNAiMet, and deacylated
E-site tRNAPhe; 6XHW for the A2058-unmethylated T. thermophilus 70S ribosome in complex
with mRNA, aminoacylated A-site Phe-NH-tRNAPhe, aminoacylated P-site fMet-NH-tRNAiMet,
and deacylated E-site tRNAPhe; 6XHX for the T. thermophilus 70S ribosome in complex with
erythromycin and protein Y; 6XHY for the T. thermophilus 70S ribosome in complex with
telithromycin, mRNA, aminoacylated A-site Phe-NH-tRNAPhe, aminoacylated P-site fMet-NHtRNAiMet, and deacylated E-site tRNAPhe.
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FIGURE LEGENDS

Figure 1 | Thermus thermophilus HB27 strain expressing Erm-like methyltransferase. (a)
Mono- and dimethylation of the A2058 residue in the domain V of the 23S rRNA by the Erm-class
methyltransferases results in high-level resistance to macrolides. (b) Multiple sequence alignment
of several known Erm-methyltransferases from mesophilic bacteria (ErmC (Staphylococcus
aureus), ErmB (Streptococcus pneumonia), and PikR2 (S. venezuelae)) with the Erm-like protein
from moderately thermophilic B. thermophilum (ErmBth, optimal growth temperature 40-45°C).
For complete sequence alignment, refer to Supplementary Fig. 2. A part of the amino acid
sequences responsible for the binding of the donor of methyl groups (SAM) is shown. Conserved
residues are highlighted in red. Black triangles point to the amino acid residues that coordinate
SAM at the active site of the enzymes. (c) Schematic map of the plasmid vector used for the
expression of ErmBth methyltransferase in Thermus thermophilus (Tth) HB27 cells. This vector
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designed to replicate in Tth carries the hygromycin B resistance marker hph under the control of
PslpA promoter (grey) and the ErmBth gene under the control of Parg promoter (orange). (d) Primer
extension analysis of the A2058-dimethylation in the 23S rRNA isolated from Erm(+) Tth cells.
Cells transformed either with the empty pBGAA1 vector (lane 1) or with the pErmBTH plasmid
were grown in the absence (lane 2) or in the presence of 0.5x MIC of ERY (lane 3). Reverse
transcriptase stalls at N6-dimethylated A2058 and produces truncated cDNA (marked with the red
arrow). Sequencing lanes are shown. (e) ErmBth-catalyzed A2058 dimethylation is stimulated by
ERY in the growth medium. The concentration of ERY was varied from 1/128 to 1/2 MIC, and
cells were grown at 48°C. The isolated rRNA was analyzed by primer extension in the presence
of dATP, dCTP, dTTP, and ddGTP. While the dideoxynucleotide ddGTP causes reverse
transcription to stop at position C2055 on all templates, the N6-dimethylation arrest cDNA
synthesis at position A2058 of the 23S rRNA. The reason for the appearance of the ‘readthrough’
cDNA product (indicated by an asterisk) is unclear but could result from either contamination of
the reaction with dGTP, or nucleotide misincorporation at C2055 during reverse transcription at
50°C. The extent of dimethylation is calculated as a ratio of the intensity of the A2058-specific
band to the sum of the intensities of the A2058-, C2055- and the readthrough bands (after
background subtraction) and indicated below the gel.
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Figure 2 | Electron density maps of N6-dimethylated (top) and unmethylated (bottom) A2058
residue of the 23S rRNA in T. thermophilus 70S ribosome. (a, c) Unbiased Fo-Fc (grey and
green mesh) and (b, d) 2Fo-Fc (blue mesh) electron difference Fourier maps of A2058 residue in
the T. thermophilus 70S ribosome contoured at 3.0σ and 1.0σ, respectively, and viewed from two
different perspectives. Grey mesh shows the Fo-Fc map after refinement with the entire modified
nucleotide omitted. Green mesh, reflecting the presence of methyl groups, shows the Fo-Fc electron
density map after refinement with the nucleotide A2058 built as a regular unmethylated adenine.
The refined models of N6-dimethylated (a, b) or unmethylated (c, d) adenine nucleotide are
displayed in the corresponding electron density maps. Carbon atoms are colored blue for the
methylated A2058 and light blue for the unmethylated A2058; nitrogens are dark blue; oxygens
are red, phosphorus atoms are green.
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Figure 3 | Structure of the Erm-modified 70S ribosome reveals the absence of any significant
rearrangements in the macrolide binding pocket. (a, b) Location of the Erm-modified
nucleotide A2058 (yellow) carrying two methyl groups (orange) in the nascent peptide exit tunnel
(NPET) of the Tth 70S ribosome relative to tRNAs and ribosomal proteins L4 (teal) and L22 (blue)
viewed as cross-cut sections through the ribosome. The 30S subunit is shown in light yellow, the
50S subunit is in light blue, the mRNA is in magenta, and the A-, P-, and E-site tRNAs are colored
green, dark blue, and orange, respectively. The phenylalanyl and formyl-methionyl moieties of the
A- and P-site tRNAs are colored magenta and blue, respectively. (c, d) Close-up views of the 23S
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rRNA nucleotides lining the macrolide binding pocket in the NPET. Nucleotides of the Ermmodified and unmodified ribosomes are shown in blue and light blue, respectively. The N6dimethylated A2058 residue is highlighted in yellow with methyl groups shown in orange. E. coli
nucleotide numbering is used. H-bonds are shown with dashed lines.
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Figure 4 | Superposition of the structures of A2058-methylated 70S ribosome and
unmethylated 70S ribosome-ERY complex. (a) Chemical structure of classical macrolide
antibiotic erythromycin (ERY). The standard numbering of carbon atoms is shown in grey. (b)
Superposition of the current structure of A2058-methylated 70S ribosome with the new highresolution structure of ribosome-bound ERY. Methylated A2058 residue is shown in blue with the
methyl groups highlighted in orange. Unmethylated A2058 residue is shown in light blue. All
structures were aligned based on domain V of the 23S rRNA. (c, d) Close-up views of the
desosamine 2´-OH group (c) and the desosamine dimethyl-amino moiety (d) relative to the methyl
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groups on m62A2058 residue. Note that there are no sterical clashes between the methyl groups of
m62A2058 and the desosamine 2´-OH group (c) or the desosamine dimethyl-amino moiety (d) of
ERY.
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Figure 5 | A water molecule mediates the interaction of macrolides with the ribosome. (a, b)
High-resolution 2Fo-Fc electron density maps (blue mesh) of ribosome-bound ERY (green, A) and
TEL (magenta, B) show that the dimethyl-amino group of a macrolide is rotated towards A2058
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and forms an H-bond with a water molecule (yellow) that is tightly coordinated by the exocyclic
N6-amino group of A2058 and the phosphate of G2505. The view in the middle insets is from the
top along the H-bond, connecting the G2505 phosphate with the water. (c) Detailed arrangement
of the H-bonds formed by the desosamine sugar of a macrolide (green) with 23S rRNA (blue) of
the ribosome via a water molecule (yellow). Hydrogens are colored white; nitrogens blue; oxygens
red (except for the water). H-bonds are shown with dashed lines. (d) Superpositioning of the new
structures of ribosome-bound ERY with the new structure of the A2058-dimethylated 70S
ribosome showing the clash between one of the m26A2058 methyl groups and the water molecule.
(e) Schematic diagram showing the molecular mechanism of resistance of A2058-dimethylated
ribosomes to macrolide antibiotics. Note that due to the inability of the dimethyl-amino group of
the m62A2068 residue to serve as an H-bond donor, it cannot participate in the coordination of the
water molecule on the ribosome. Moreover, the methyl groups physically displace the water
molecule leaving the G2505 phosphate and the dimethyl-amino group of macrolide desosamine
without an H-bond partner.
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